Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: Anti-myostatin monoclonal antibody

Domagrozumab

Plain-language summaryIntrigue 50 / 100

Domagrozumab (PF-06252616) is Pfizer’s second-generation anti-myostatin antibody, designed for higher affinity than stamulumab. The pivotal phase 2 trial in Duchenne muscular dystrophy (2018) showed meaningful muscle mass increases on MRI but failed to demonstrate functional benefit on the primary motor outcome, leading Pfizer to terminate the program. The pattern (muscle mass without function) has now repeated across nearly every anti-myostatin compound tested in muscular dystrophy and is the central puzzle of the field: blocking myostatin reliably grows muscle but does not seem to make patients meaningfully stronger. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

32/100

Failed DMD phase 2 retained as a selective myostatin probe for mechanistic research

Look, the anti-myostatin story has not gone well for anyone. Wyeth’s stamulumab, Lilly’s landogrozumab, Regeneron’s trevogrumab – the list of humanized antibodies that neutralized myostatin beautifully in animals and then failed in humans is long enough now that we have to take the lesson seriously. Domagrozumab is the Pfizer entry in that cohort, and its 2018 phase 2 in DMD produced the most clinically instructive kind of failure: muscle mass went up on MRI, but the 6-minute walk test and North Star Ambulatory Assessment didn’t move.

That result isnt just a dead end – its actually the most scientifically interesting thing about this compound. It suggests the limiting factor in DMD isnt myostatin-mediated mass suppression; its the relentless mechanical damage from dystrophin deficiency. You can add muscle, and the dystrophic fiber still breaks down faster than myostatin inhibition can compensate. Thats genuinely clarifying biology, and domagrozumab helped establish it.

The novelty problem is real. Myostatin inhibition as a concept is nearly thirty years old – the McPherron double-muscle mouse dates to 1997. The IgG1 antibody approach to neutralizing GDF-8 is well-trodden at this point, and domagrozumab doesnt have a mechanism angle that distinguishes it meaningfully from the compounds that came before. Its not doing anything the class hadn’t already tried, and the mechanism score reflects that: single-receptor neutralization in a saturated, largely-failed class.

Differentiation is the weakest score here. Against other anti-myostatin antibodies, domagrozumab occupies no particular best-in-class position. Its affinity for myostatin is high, it’s humanized, its PK in humans is characterized – that makes it a functional research tool, but not a leading one. We think the ActRII-pathway inhibitors (luspatercept, bimagrumab) are more interesting if you want to study muscle anabolism broadly, because they engage the wider TGF-beta ligandome and produce cleaner clinical signals.

What domagrozumab does retain is probe value for investigators who specifically want myostatin-selective inhibition, as opposed to the broader ligand traps that catch activin, GDF-11, and other TGF-beta family members alongside GDF-8. If your question is specifically about GDF-8 rather than the whole ActRIIB ligandome, this compound gives you a cleaner experimental handle. Thats a narrow utility but its real.

The phase 2 evidence is actually quality evidence – well-designed RCT, adequate N, prespecified functional endpoints – it just produced a negative answer. The evidence quality score is respectable for that reason. The translational signal, though, is genuinely negative: the mechanism did not translate to clinical benefit in the target population, and that distinction matters for how we weight this overall.

Bench scientists studying DMD pathophysiology, the myostatin signaling axis, or the dissociation between muscle mass and functional output in dystrophic tissue will find this a documented, human-characterized probe. For everyone else, the evidence has made the case for moving on.

Novelty

28

Mechanism promise

35

In-category differentiation

20

Evidence quality

50

Translational signal

22

Research bench value

48

Rationale Domagrozumab’s 2018 phase 2 in DMD decisively closed the clinical case: muscle mass increases on MRI did not translate to functional gains, and Pfizer walked away. Scores are suppressed by low novelty in a 25-year-old target class, no meaningful differentiation from other failed anti-myostatin antibodies, and a clearly negative translational signal; residual probe value for GDF-8-selective biology keeps bench_value from bottoming out.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Anti-myostatin monoclonal antibody

A humanized anti-myostatin monoclonal antibody developed at Pfizer for Duchenne muscular dystrophy; phase 2 trial failed.

Abstract

Domagrozumab (PF-06252616; humanized IgG1 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized anti-myostatin monoclonal antibody developed at Pfizer. The compound is selective for myostatin (GDF-8) with high affinity, designed to neutralize circulating myostatin in Duchenne muscular dystrophy. Phase 2 trial in DMD (2018) demonstrated muscle mass increases on MRI but no significant improvement in functional endpoints (6-minute walk test, North Star Ambulatory Assessment); Pfizer discontinued development. The trial result reinforced a broader concern about myostatin inhibition in DMD: muscle mass gains may not translate to clinical benefit if the underlying dystrophin deficiency continues to cause fiber damage. Used as a research compound for selective myostatin neutralization in DMD context.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-361Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Landogrozumab

Plain-language summaryIntrigue 48 / 100

Landogrozumab (LY2495655) is Eli Lilly’s anti-myostatin antibody, built as an IgG4 isotype to reduce immune effector function compared to the IgG1 antibodies in the class. Phase 2 trials targeted cancer cachexia, hip-fracture-associated muscle wasting, and elective total hip arthroplasty recovery, all populations where preserving lean mass might affect functional outcomes. The trials produced muscle mass increases but limited functional benefit, echoing the pattern seen across the entire myostatin-blocking class. The program was discontinued. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

40/100

Phase 2-stalled anti-myostatin mAb with real mass signal but inconsistent functional translation

Look, the anti-myostatin story is old enough to have a college degree. McPherron’s 1997 knockout mice, the early Wyeth antibody programs, Pfizer’s domagrozumab stumbling in Duchenne — the field has been trying to turn myostatin inhibition into a clinical win for a long time, and the wins keep coming out smaller than hoped. Landogrozumab doesn’t escape that pattern.

What Lilly did right is the isotype choice. IgG4 instead of IgG1 means substantially less Fc receptor engagement and complement activation, which matters a lot when you’re talking about chronic dosing in a frail or immunocompromised population. That’s not just a packaging detail; it reduces one of the real confounds in interpreting antibody studies. For any investigator who wants to neutralize myostatin cleanly without layering in Fc-mediated biology, that IgG4 format is genuinely useful.

The phase 2 data tells a complicated story. Trials in cancer cachexia, hip-fracture-associated sarcopenia, and statin-associated myopathy all showed real muscle mass increases — roughly 4 percent at six months, which is statistically detectable and mechanistically consistent. The problem is functional outcomes. Grip strength, walking speed, functional independence scores… inconsistent across the board. This is, honestly, the central unresolved question of the entire myostatin inhibition class. You can grow the muscle, but does that muscle do anything? The answer so far is: sometimes, not reliably. Development never advanced to phase 3, which tells you what Lilly concluded.

We think the comparison to bimagrumab is important context here. Bimagrumab targets ActRIIB directly, capturing not just myostatin but activin A and other ligands — that broader inhibition profile seems to produce more meaningful functional signals in some populations, particularly when combined with caloric restriction. Landogrozumab’s narrower myostatin-specific approach means cleaner mechanistic attribution in a research setting, but it also means you’re probably leaving efficacy on the table if the goal is actual functional improvement.

For bench use, the compound has a real niche. Investigators studying myostatin signaling, cachexia biology, or muscle fiber hypertrophy mechanisms have a validated, well-characterized tool here. The reduced effector function matters for clean readouts. Thats not nothing. But the clinical development story is a ceiling, not a floor, and anyone building a research program around this class needs to account for the mass-without-function problem thats defined every anti-myostatin program so far.

Novelty

32

Mechanism promise

42

In-category differentiation

30

Evidence quality

52

Translational signal

38

Research bench value

58

Rationale Scored down on novelty and differentiation because the anti-myostatin antibody class is 20+ years old and functionally outcompeted by ActRII-targeting approaches like bimagrumab; bench value is the relative bright spot because the IgG4 isotype makes it a clean myostatin probe with reduced Fc confounding for muscle biology studies. Evidence quality reflects real Lilly-backed phase 2 trials across three indications, but the mass-without-function pattern and halted development cap translational enthusiasm.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Anti-myostatin monoclonal antibody

A humanized anti-myostatin monoclonal antibody developed at Eli Lilly; investigated for cancer cachexia and muscle wasting.

Abstract

Landogrozumab (LY2495655; humanized IgG4 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized anti-myostatin monoclonal antibody developed at Eli Lilly. The IgG4 isotype reduces effector function (Fc receptor engagement, complement activation) compared to IgG1, theoretically reducing immunogenicity for chronic dosing. Phase 2 trials in cancer cachexia, hip-fracture-associated muscle loss, and statin-associated muscle pain demonstrated muscle mass increases of approximately 4 percent at 6 months but inconsistent functional improvement. Development has not advanced to phase 3. Used as a research compound for selective myostatin neutralization with reduced effector function.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-362Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.